FIGURE 3.

(A) Kaplan–Meier estimate for probability of survival in elderly patients (≥70 years of age) who received a doublet and who received capecitabine as first-line chemotherapy. Survival was superior for patients who received a doublet or capecitabine alone compared with patients who selected no chemotherapy (log-rank p < 0.001 and p = 0.025 respectively). (B) Kaplan–Meier estimate of progression-free survival in elderly patients (≥70 years of age) treated with a doublet or capecitabine alone (log-rank p = 0.009). BSC = best supportive care; HR = hazard ratio; CI = confidence interval.